Chronic myeloid leukemia (CML) is a blood and bone marrow cancer. It results in the production of too many immature blood cells, called myeloblasts. Doctors can classify CML into 3 phases using lab ...
Chronic myeloid leukemia (CML) is highly treatable. With an experienced care team, most people do well for many years on medicines they take at home. At Fred Hutch Cancer Center, our CML experts ...
Given the widespread introduction of tyrosine kinase inhibitors (TKIs), we evaluated the cost associated with chronic myelogenous leukemia (CML) care compared with the cost of care for patients with ...
Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy (busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such as imatinib. Although imatinib ...
Chronic myeloid leukemia (CML) is a hematopoietic malignancy characterized by BCR-ABL1 gene fusion. The immune microenvironment, implicated in relapse and drug resistance, poses significant challenges ...
Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor–refractory threonine-to-isoleucine mutation at position 315 ...
Epidemiology and Risk Factors for the Development of Infectious Complications in Newly Diagnosed Multiple Myeloma: A Multicenter Prospective Cohort Study in Latin America We retrospectively reviewed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results